AstraZeneca reports major Phase III breakthrough in IgA kidney disease trial
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
As official healthcare partner, ShardaCare deployed dedicated medical teams, emergency services, and on-site healthcare infrastructure
First installation of AI-powered AMULET SOPHINITY at NM Medical aims to strengthen early breast cancer detection
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
The launch comes against the backdrop of a significant public health burden
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
We are building the bridge between complex molecular data and everyday clinical decisions
The session created a platform for meaningful discussions on the challenges of the disease and the importance of timely intervention
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
Seasoned pharmaceutical marketing leader brings extensive experience in brand management, sales strategy, and digital engagement to the expanded leadership role
Subscribe To Our Newsletter & Stay Updated